廣東中翔新材料簽約德米薩智能ERP加強企業(yè)管理水平
碩鋮工業(yè)簽約德米薩智能進銷存系統(tǒng)提升企業(yè)管理水平
燊川實業(yè)簽約德米薩醫(yī)療器械管理軟件助力企業(yè)科學發(fā)展
森尼電梯簽約德米薩進銷存系統(tǒng)優(yōu)化企業(yè)資源管控
喜報!熱烈祝賀德米薩通過國際CMMI3認證
德米薩推出MES系統(tǒng)助力生產(chǎn)制造企業(yè)規(guī)范管理
德米薩醫(yī)療器械管理軟件通過上海市醫(yī)療器械行業(yè)協(xié)會評審認證
德米薩ERP助力客戶成功對接中石化易派客平臺
選擇進銷存軟件要考慮哪些因素
德米薩告訴您為什么說ERP系統(tǒng)培訓很重要?
Recombinant Human ACE2/ACEH Protein,hFc Tag性能參數(shù),分子別名(Synonyms)ACE2;ACEH;ACE-2表達區(qū)間及表達系統(tǒng)(Source)HumanACE2/ACEHProteinisexpressedfromHEK293withhFctagattheC-Terminus.ItcontainsGln18-Ser740.[Accession|Q9BYF1-1]分子量大?。∕olecularWeight)TheproteinhasapredictedMWof109.2kDa.Duetoglycosylation,theproteinmigratesto115-130kDabasedonSDS-PAGEresult.Endotoxin)Lessthan1EUperμgbytheLALmethod.純度(Purity)>95%asdeterminedbySDS-PAGEandHPLC.活性(Activity)ELISAData:ImmobilizedSARS-COV-2SpikeS(B.1.1.529/Omicron)Trimer,HisTagat1μg/ml(100μl/well)ontheplate.DoseresponsecurveforHumanACE2,hFcTagwiththeEC50of13.7ng/mldeterminedbyELISA.制劑(Formulation)Lyophilizedfrom0.22μmfilteredsolutioninPBS(pH7.4).Normally8%trehaloseisaddedasprotectantbeforelyophilization.重構方法(Reconstitution)Centrifugethetubebeforeopening.Reconstitutingtoaconcentrationmorethan100μg/mlisrecommended.Dissolvethelyophilizedproteinindistilledwater.IdeS 具有獨特的底物選擇性,可以作為工具酶應用于抗體類藥物或抗體融合蛋白藥物的結構表征分析。Recombinant Human Complement Factor D/CFD (His Tag)
SARS-CoV-2,whichcausestheglobalpandemiccoronavirusdisease2019(Covid-19),belongstoafamilyofvirusesknownascoronaviruses.TheSARS-CoV-2Sproteinisaglycoproteinthatmediatesmembranefusionandviralentry.TheRBDofSARS-CoV-2bindsametallopeptidase,angiotensin-convertingenzyme2(ACE-2).SeveralemergingSARS-CoV-2genomeshavebeenidentifiedincludingtheOmicron,orB.1.1.529,variant.FirstidentifiedinNovember2021inSouthAfrica,theOmicronvariantquicklybecamethepredominantSARS-CoV-2variantandisconsideredavariantofconcern(VOC).TheOmicronvariantcontains15mutationsinRBDdomainthatpotentiallyaffectviralfitnessandtransmissibility.ThemajorityofthemutationsareinvolvedinACE-2bindingandOmicronbindsACE-2withgreateraffinity,potentiallyexplainingitsincreasedtransmissibility.Severalofthesemutationsarealsoidentifiedinfacilitatingimmuneescapeandreducingneutralizationactivitytoseveralmonoclonalantibodies.Recombinant Human CDCP1 (His Tag)FGF-18與FGF R2C,F(xiàn)GF R3C以及高爾基蛋白GLG1結合,并誘導星形膠質(zhì)細胞和小膠質(zhì)細胞。
Cas9核酸酶是一種引導RNA引導的核酸內(nèi)切酶,可以催化雙鏈DNA的裂解。這種靶向核酸酶是一種高精度的基因組編輯的有力工具。Cas9蛋白與CRISPR/Cas9系統(tǒng)的引導RNA(gRNA)成分形成一個非常穩(wěn)定的核糖白(RNP)復合物。Cas9RNP復合物可以在進入細胞后,通過添加一個N端核定位信號(NLS),增加入核效率。YEASEN開發(fā)的NLS-Cas9核酸酶在蛋白的N端包含一個核定位序列(NLS),以增加入核切割效率。產(chǎn)品特點如下:無DNA:沒有外部DNA添加。安全性好:野生型Cas9蛋白,無標簽。可應用于:通過體外DNA切割篩選高效和特異性靶向gRNA。產(chǎn)品信息貨號11366ES60/11366ES76規(guī)格100μg/500μg來源重組Cas9來源于大腸桿菌物種化膿性鏈球菌標簽無分子量160KDa濃度10mg/mL(50μg);10mg/mL(100μg)
N-糖苷酶 F (PNGase F)酶活定義(UnitDefinition)1個酶活力單位指在10μL的反應體系中,37℃條件下1小時從10μg變性RNaseB中除去超過95%的碳水化合物所需要的酶量。儲存條件-15~-25℃保存,有效期1年。使用說明變性條件下蛋白質(zhì)去糖基化1)在水中加入1μLBuffer1和目標糖蛋白(1-20μg),至終體積10μL;2)100℃溫度下煮沸10min使其變性,冰上冷卻,離心10秒;3)加入2μL的Buffer2、2μL的10%NP-40、6μL去離子水,總反應體積20μL;4)加入0.2~0.5μL的PNGase,輕輕混勻。在37℃孵育1-3h。非變性條件下蛋白質(zhì)去糖基化1)在水中加入2μL的Buffer2和目標糖蛋白(1-20μg)至體積為20μL。2)加入0.5~1μL的PNGaseF,輕輕混勻。3)37°C孵育4-24h。注意:在變性條件下大多數(shù)底物能夠更好的去糖基化,在非變性條件下可能需要增加PNGaseF的量和延長孵育時間。人血清白蛋白(HSA)是脂類等物質(zhì)的轉運載體,其主要生理功能是調(diào)節(jié)血漿pH值和維持血漿滲透壓。
Dabigatranetexilatemesylate,又稱甲磺酸達比加群酯,是可口服的凝血酶抑制劑,是一種抗凝藥,通過競爭結合凝血酶的纖維蛋白特異結合位點,阻礙纖維蛋白生成,從而抑制血栓的形成。產(chǎn)品信息英文別名(EnglishSynonym)Dabigatranetexilatemesylate,Pradaxa,BIBR1048MS,Dabigatranetexilatemethanesulfonate中文名稱(ChineseName)甲磺酸達比加群酯,達比加群酯甲磺酸鹽靶點(Target)Thrombin通路(Pathway)Protease/MetabolicEnzyme--ThrombinCAS號(CASNO.)872728-81-9分子式(Formula)C35H45N7O8S分子量(MolecularWeight)723.84外觀(Appearance)粉末純度(Purity)≥98%溶解性(Solubility)溶于DMSO運輸和保存方法-25~-15℃保存,有效期3年。使用方法【數(shù)據(jù)來自于公開發(fā)表的文獻,供參考,具體使用濃度請參考相關文獻,并根據(jù)自身實驗條件(如實驗目的,細胞種類,培養(yǎng)特性等)進行摸索和優(yōu)化?!縿游飳嶒灒w內(nèi)實驗)在體內(nèi),口服dabigatranetexilate在大10-50mg/kg)和恒河猴(1-5mg/kg)時間劑量依賴性地表現(xiàn)出抗凝效果。猴痘病毒(Monkeypox Virus, MPXV)屬于正痘病毒屬。一般來說,同屬病毒具有相似的生物學特性。Recombinant Human FSHB Protein,His Tag
AFGF在調(diào)節(jié)細胞存活,細胞分裂,血管生成,細胞分化和細胞遷移中起重要作用。Recombinant Human Complement Factor D/CFD (His Tag)
Angiotensin I Converting Enzyme (ACE-2), also called ACEH (ACE homologue), is a dimeric, zinc-dependent metalloprotease of the ACE family that also includes somatic and germinal ACE. ACE-2 mRNA is found at high levels in heart, testis, and kidney and at lower levels in a wide variety of tissues. ACE-2 is the SARS-CoV and SARS-CoV2 Spike protein receptor in vivo, functions catalytically as a carboxypeptidase to cleave several substrates including angiotensins I and II, and acts as a partner for B0AT1-family amino acid transporters. Through these functions, ACE-2 has been shown to be involved in several diseases including SARS, COVID19, acute lung injury, heart disease, liver and lung fibrosis, inflammatory lung disease, and cardiopulmonary disease . Full length ACE-2 protein includes an extracellular region composed of a single N-terminal peptidase domain and C-terminal collectrin-like domain (CLD), a transmembrane domain, and a short cytoplasmic tail. The N-terminal peptidase region is required for binding to SARS-CoV and SARS-CoV2 spike proteins, while the CLD contains a region that promotes dimerization and association with amino acid transporters.Recombinant Human Complement Factor D/CFD (His Tag)
浦斯瑞(上海)生物醫(yī)藥有限公司是一家有著雄厚實力背景、信譽可靠、勵精圖治、展望未來、有夢想有目標,有組織有體系的公司,堅持于帶領員工在未來的道路上大放光明,攜手共畫藍圖,在江蘇省等地區(qū)的化工行業(yè)中積累了大批忠誠的客戶粉絲源,也收獲了良好的用戶口碑,為公司的發(fā)展奠定的良好的行業(yè)基礎,也希望未來公司能成為*****,努力為行業(yè)領域的發(fā)展奉獻出自己的一份力量,我們相信精益求精的工作態(tài)度和不斷的完善創(chuàng)新理念以及自強不息,斗志昂揚的的企業(yè)精神將**浦斯瑞(上海)生物醫(yī)藥供應和您一起攜手步入輝煌,共創(chuàng)佳績,一直以來,公司貫徹執(zhí)行科學管理、創(chuàng)新發(fā)展、誠實守信的方針,員工精誠努力,協(xié)同奮取,以品質(zhì)、服務來贏得市場,我們一直在路上!